Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Price Negotiation In Part D: Big Savings On Revlimid, Ibrance, Xtandi Projected in CAP Analysis

Executive Summary

As Democrats in the US Congress work to move legislation empowering the Health and Human Services Department to negotiate drug prices directly with manufacturers, the Center For American Progress releases an analysis on which drugs would be targeted by House bill HR 3 and how much prices could be reduced.

You may also be interested in...



Patent Thickets And Legislative Logjams

US Senate hearing on pharmaceutical competition brought renewed interest to idea of pruning so-called ‘patent thickets.’ But the choking growth of legislative proposals may itself by hampering progress on Capitol Hill.

Drug Pricing Reforms To Underwrite Major Part Of Senate ‘Soft’ Infrastructure Legislation

Senate Finance Committee directed to provide ‘nearly all’ of the spending offsets for the $3.5tn package; Committee chair Ron Wyden is focused on authorizing the US government to directly negotiate drug prices in Medicare.

The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure

The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel